-
公开(公告)号：US10829486B2
公开(公告)日：2020-11-10
申请号：US16272506
申请日：2019-02-11
Applicant: ENANTA PHARMACEUTICALS, INC.
Inventor： Ruichao Shen , Jun Ma , Guoqiang Wang , Xuechao Xing , Yat Sun Or
Abstract: The present invention provides compounds of Formula (I): pharmaceutical compositions comprising these compounds and methods of using these compounds to treat or prevent a disease or disorder mediated by FXR. Specifically, the present invention relates to isoxazole derivatives useful as agonists for FXR, and methods for their preparation and use.
-
公开(公告)号：US20200317717A1
公开(公告)日：2020-10-08
申请号：US16854334
申请日：2020-04-21
Applicant: Enanta Pharmaceuticals, Inc.
Inventor： Guoqiang Wang , Yong He , Brett Granger , Xuechao Xing , Yat Sun Or
Abstract: The present invention relates to processes for preparing compounds of Formula (I) and Formula (II): These compounds are useful as FXR or TGR5 modulators. The present invention also relates to processes for the preparation of the compounds of Formula (III), Formula (IV), Formula (V), and Formula (VI), The present invention also relates to a process for the preparation of compounds (VII), (VIII) and (IX),
-
公开(公告)号：US10696713B2
公开(公告)日：2020-06-30
申请号：US16222380
申请日：2018-12-17
Applicant: Enanta Pharmaceuticals, Inc.
Inventor： Guoqiang Wang , Yat Sun Or , Ruichao Shen , Jiang Long , Peng Dai , Xuechao Xing , Jing He
Abstract: The present invention provides compounds of Formula I, pharmaceutical compositions comprising these compounds and methods of using these compounds to prevent or treat FXR-mediated or TGR5-mediated diseases or conditions.
-
公开(公告)号：US20190194216A1
公开(公告)日：2019-06-27
申请号：US16217749
申请日：2018-12-12
Applicant: Enanta Pharmaceuticals, Inc.
Inventor： Yat Sun Or , Jun Ma , Guoqiang Wang , Xuechao Xing , Ruichao Shen , Bin Wang
IPC: C07D491/048 , C07D493/04 , C07D487/04 , C07D417/14
CPC classification number: C07D491/048 , C07D417/14 , C07D487/04 , C07D493/04
Abstract: The present invention provides compounds of Formula (I), and pharmaceutically acceptable salts thereof, as well as pharmaceutical compositions comprising these compounds and methods of using these compounds to prevent or treat FXR-mediated or TGR5-mediated diseases or conditions.
-
公开(公告)号：US10246439B2
公开(公告)日：2019-04-02
申请号：US15988783
申请日：2018-05-24
Applicant: ENANTA PHARMACEUTICALS, INC.
Inventor： Brett Granger , Guoqiang Wang , Ruichao Shen , Jun Ma , Xuechao Xing , Jing He , Yong He , Jiang Long , Bin Wang , Yat Sun Or
IPC: C07D401/14 , C07D487/08 , C07D491/08 , C07D513/04 , C07D417/14
Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts and esters thereof: which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcohol steatohepatitis disease (NASH).
-
Patent Agency Ranking
公开(公告)号：US20180362502A1
公开(公告)日：2018-12-20
申请号：US15988783
申请日：2018-05-24
Applicant: ENANTA PHARMACEUTICALS, INC.
Inventor： Brett Granger , Guoqiang Wang , Ruichao Shen , Jun Ma , Xuechao Xing , Jing He , Yong He , Jiang Long , Bin Wang , Yat Sun Or
IPC: C07D401/14 , C07D417/14 , C07D513/04 , C07D491/08 , C07D487/08
CPC classification number: C07D401/14 , C07D417/14 , C07D487/08 , C07D491/08 , C07D513/04
Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts and esters thereof: which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcohol steatohepatitis disease (NASH).
-
公开(公告)号：US10149835B2
公开(公告)日：2018-12-11
申请号：US15597431
申请日：2017-05-17
Applicant: Enanta Pharmaceuticals, Inc.
Inventor： Yat Sun Or , Xuechao Xing , Ruichao Shen , Bin Wang , Brett Granger , Jun Ma , Jing He , Jiang Long , Yong He , Guoqiang Wang
IPC: A61K31/42 , C07D225/04 , C07D213/127 , C07D261/08 , C07C317/38
Abstract: The present invention provides compounds of Formula I: and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising these compounds and methods of using these compounds to treat or prevent a disease or disorder mediated by FXR. Specifically, the present invention relates to isoxazole derivatives useful as agonists for FXR and methods for their preparation and use.
-
公开(公告)号：US10080743B2
公开(公告)日：2018-09-25
申请号：US15497359
申请日：2017-04-26
Applicant: Enanta Pharmaceuticals, Inc.
Inventor： Yat Sun Or , Bin Wang , Xuechao Xing , Ruichao Shen , Brett Granger , Jun Ma , Jing He , Yong He , Jiang Long , Guoqiang Wang
IPC: C07D261/08 , C07D413/12 , A61K31/42 , A61K31/422
CPC classification number: A61K31/42 , A61K31/422 , C07D261/08 , C07D413/12
Abstract: The present invention provides compounds of Formula I, pharmaceutical compositions comprising these compounds and methods of using these compounds to treat or prevent a disease or disorder mediated as FXR modulators. Specifically, the present invention relates to isoxazole derivatives useful as agonists for FXR, and methods for their preparation and use.
-
公开(公告)号：US20180141941A1
公开(公告)日：2018-05-24
申请号：US15793554
申请日：2017-10-25
Applicant: Enanta Pharmaceuticals, Inc.
Inventor： Jing He , Guoqiang Wang , Ruichao Shen , Xuechao Xing , Bin Wang , Jun Ma , Yat Sun Or
CPC classification number: C07D451/02 , A61P1/00 , A61P1/16 , A61P3/00 , A61P9/00 , A61P11/00 , A61P13/12
Abstract: The present invention provides compounds of Formula I, Pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising these compounds and methods of using these compounds to prevent or treat FXR-mediated or TGR5-mediated diseases or conditions.
-
40.发明申请Bile Acid Derivatives as FXR/TGR5 Agonists and Methods of Use Thereof 审中-公开胆酸衍生物作为FXR / TGR5激动剂及其使用方法公开(公告)号：US20160176917A1
公开(公告)日：2016-06-23
申请号：US14976294
申请日：2015-12-21
Applicant: Enanta Pharmaceuticals, Inc.
Inventor： Guoqiang Wang , Yat Sun Or , Ruichao Shen , Jiang Long , Peng Dai , Xuechao Xing , Jing He
CPC classification number: C07J43/003 , C07J41/0055 , C07J41/0088
Abstract: The present invention provides compounds of Formula I, pharmaceutical compositions comprising these compounds and methods of using these compounds to prevent or treat FXR-mediated or TGR5-mediated diseases or conditions.
Abstract translation: 本发明提供式I化合物，包含这些化合物的药物组合物以及使用这些化合物预防或治疗FXR介导的或TGR5介导的疾病或病症的方法。
-
-
-
-
-
-
-
-
-
Search Results
93
records
(took 0.027 seconds)
